Cephalon reaches $1 billion milestone in annual revenue

02/17/2005 | Philadelphia Inquirer, The

Cephalon's announcement puts it in a league with only eight other U.S. biotechnology companies, and the firm's CEO said he expects revenues to double to $2 billion by the end of 2008. In the coming two years, Cephalon faces a loss of patent for two of its biggest products, Provigil and Actiq, and one analyst said the company would need to "ramp up sales in the attention-deficit market" and get approval of another drug now in Phase III clinical trials to offset the expected generic competition for Provigil and Actiq.

View Full Article in:

Philadelphia Inquirer, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Actuary
Meridian Health Plan
Detroit, MI
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Children's Health Plan
Houston, TX
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX